2020
The association of lorg-term outcome and biological sex in patients with acute heart failure from different geographic regions
MOTIEJUNAITE, J., E. AKIYAMA, A. COHEN-SOLAL, A. P. MAGGIONI, C. MUELLER et. al.Základní údaje
Originální název
The association of lorg-term outcome and biological sex in patients with acute heart failure from different geographic regions
Autoři
MOTIEJUNAITE, J. (440 Litva), E. AKIYAMA (392 Japonsko), A. COHEN-SOLAL (250 Francie), A. P. MAGGIONI (380 Itálie), C. MUELLER (756 Švýcarsko), D. J. CHOI (178 Konžská republika), A. KAVOLIUNIENE (440 Litva), J. CELUTKIENE (440 Litva), Jiří PAŘENICA (203 Česká republika, domácí), J. LASSUS (246 Finsko), K. KAJIMOTO (392 Japonsko), N. SATO (392 Japonsko), O. MIRO (724 Španělsko), W. F. PEACOCK (840 Spojené státy), Y. MATSUE (392 Japonsko), A. A. VOORS (528 Nizozemské království), C. S. P. LAM (702 Singapur), J. A. EZEKOWITZ (124 Kanada), A. AHMED (840 Spojené státy), G. C. FONAROW (840 Spojené státy), E. GAYAT (250 Francie), V. REGITZ-ZAGROSEK (276 Německo) a A. MEBAZAA (250 Francie, garant)
Vydání
European heart journal, Oxford, Oxford University Press, 2020, 0195-668X
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30201 Cardiac and Cardiovascular systems
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Odkazy
Impakt faktor
Impact factor: 29.983
Kód RIV
RIV/00216224:14110/20:00116018
Organizační jednotka
Lékařská fakulta
UT WoS
000522664500012
Klíčová slova anglicky
Acute heart failure; Gender; Biological sex; Mortality; Prognosis
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 12. 5. 2021 13:15, Mgr. Tereza Miškechová
Anotace
V originále
Aims Recent data from national registries suggest that acute heart failure (AHF) outcomes might vary in men and women, however, it is not known whether this observation is universal. The aim of this study was to evaluate the association of biological sex and 1-year all-cause mortality in patients with AHF in various regions of the world. Methods and Results We analysed several AHF cohorts including GREAT registry (22 523 patients, mostly from Europe and Asia) and OPTIMIZE-HF (26 376 patients from the USA). Clinical characteristics and medication use at discharge were collected. Hazard ratios (HRs) for 1-year mortality according to biological sex were calculated using a Cox proportional hazards regression model with adjustment for baseline characteristics (e.g. age, comorbidities, clinical and laboratory parameters at admission, Left ventricular ejection fraction). In the GREAT registry, women had a Lower risk of death in the year following AHF [HR 0.86 (0.79-0.94), P< 0.001 after adjustment]. This was mostly driven by northeast Asia [n=9135, HR 0.76 (0.67-0.87), P< 0.001], while no significant differences were seen in other countries. In the OPTIMIZE-HF registry, women also had a tower risk of 1-year death [HR 0.93 (0.89-0.97), P < 0.001]. In the GREAT registry, women were less often prescribed with a combination of angiotensin-converting enzyme inhibitors and beta-Mockers at discharge (50% vs. 57%, P = 0.001). Conclusion Globally women with AHF have a lower 1-year mortality and less evidenced-based treatment than men. Differences among countries need further investigation. Our findings merit consideration when designing future global clinical trials in AHF.